Denise Yardley, MD
Medical Oncologist

Denise Yardley, MD

Specialities

  • Breast cancer
  • Benign-hematology
  • Clinical trials and research advancements

Education

Medical Degree: Medical College of Georgia
Residency: University of Texas Southwestern Medical Center
Fellowship: University of Texas Southwestern Medical Center

Location

335 24th Avenue North, Suite 200  
Nashville, Tennessee 37203 
Phone: 615-329-7640 
Fax: 615-234-7723 

Language

English

Biography

Dr. Yardley is a board-certified medical oncologist and hematologist at SCRI Oncology Partners and serves as the associate director of breast cancer research at SCRI. Prior to joining the team at SCRI, she served as the medical director at the University of Texas Southwestern’s Center for Breast Care. A diplomate of the American Board of Internal Medicine, Medical Oncology and Hematology, she is also a recipient of the American Cancer Society Clinical Oncology Career Development Award. Dr. Yardley has been caring for patients in Nashville for over 20 years.

Philosophy

Dr. Yardley is passionate about providing access to the latest advancements in breast cancer care. She approaches each patient and their family members with knowledge and compassion. She provides individualized treatment plans tailored to each patient’s unique needs and goals for their health.

Relevant Research

Therapeutics Advances in Medical Oncology

Therapeutics Advances in Medical Oncology

Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2- advanced breast cancer

Cancer Research

Cancer Research

Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer

Lancet Oncology

Lancet Oncology

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study